{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T19:39:20Z","timestamp":1754163560701,"version":"3.41.2"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Patients with a germline BRCA pathogenic variant (gBRCA-PV) and advanced high grade ovarian carcinoma (aHGOC) experience higher hematologic adverse events (HAEs) when receiving platinum salts and ionizing radiations, compared to non-carriers, due to a possible higher susceptibility of the hemopoietic stem cells to DNA targeting agents. However, the incidence of PARP inhibitor (PARPi)-related HAEs according to the gBRCA-PV status is currently unknown.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and Methods<\/jats:title>\n                  <jats:p>We conducted a single-center retrospective cohort study to describe the occurrence of HAEs in patients with aHGOC receiving \u22658 weeks of maintenance PARPi in any line of therapy, comparing gBRCA-PVs carriers to non-carriers. HAEs were manually identified by searching the patients\u2019 electronic medical records and classified by CTCAE v5.0. The main endpoint was the incidence rate of any HAE (ie, anaemia, neutropenia, or thrombocytopenia) of grade 2 or more (G\u2005\u2265\u20052).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>One hundred and sixty-six patients were included; 95 (57%) had a gBRCA-PV. In total, 162 incident cases of G\u2005\u2265\u20052 HAEs were reported over 255.3 person-years. The incidence rates of G\u2005\u2265\u20052 HAEs were 1003\/1000 person-years in gBRCA-PV carriers and 993\/1000 person-years in non-carriers. No difference in the incidence rate of G\u2005\u2265\u20052 HAEs emerged comparing gBRCA-PV carriers to non-carriers (crude-incidence rate ratio [IRR]: 1.01; 95% CI: 0.72, 1.43; P\u2005=\u2005.96), even after adjusting for the type of PARPi (Mantel-Haenszel IRR: 0.99; 95% CI: 0.67, 1.46).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Patients with aHGOC and a gBRCA-PV do not experience higher PARPi-related HAEs compared to non-gBRCA-PV carriers, unlike platinum salt-related HAEs.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyae330","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T12:55:09Z","timestamp":1732798509000},"source":"Crossref","is-referenced-by-count":1,"title":["Germline <i>BRCA<\/i> pathogenic variants and hematologic adverse events in patients with ovarian carcinoma receiving PARP inhibitors: a retrospective cohort study"],"prefix":"10.1093","volume":"30","author":[{"given":"Carmine","family":"Valenza","sequence":"first","affiliation":[{"name":"Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS , Milan ,","place":["Italy"]},{"name":"University of Milan Department of Oncology and Hemato-Oncology, , Milan ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleonora","family":"Nicol\u00f2","sequence":"additional","affiliation":[{"name":"Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS , Milan ,","place":["Italy"]},{"name":"University of Milan Department of Oncology and Hemato-Oncology, , Milan ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Mongillo","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, European Institute of Oncology, IRCCS , Milan ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1672-9560","authenticated-orcid":false,"given":"Dario","family":"Trapani","sequence":"additional","affiliation":[{"name":"Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS , Milan ,","place":["Italy"]},{"name":"University of Milan Department of Oncology and Hemato-Oncology, , Milan ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jalissa","family":"Katrini","sequence":"additional","affiliation":[{"name":"Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS , Milan ,","place":["Italy"]},{"name":"University of Milan Department of Oncology and Hemato-Oncology, , Milan ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Boldrini","sequence":"additional","affiliation":[{"name":"Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS , Milan ,","place":["Italy"]},{"name":"University of Milan Department of Oncology and Hemato-Oncology, , Milan ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Boscolo Bielo","sequence":"additional","affiliation":[{"name":"Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS , Milan ,","place":["Italy"]},{"name":"University of Milan Department of Oncology and Hemato-Oncology, , Milan ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grazia","family":"Castellano","sequence":"additional","affiliation":[{"name":"Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS , Milan ,","place":["Italy"]},{"name":"University of Milan Department of Oncology and Hemato-Oncology, , Milan ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Guidi","sequence":"additional","affiliation":[{"name":"Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS , Milan ,","place":["Italy"]},{"name":"University of Milan Department of Oncology and Hemato-Oncology, , Milan ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gloria","family":"Pellizzari","sequence":"additional","affiliation":[{"name":"Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS , Milan ,","place":["Italy"]},{"name":"University of Milan Department of Oncology and Hemato-Oncology, , Milan ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacopo","family":"Villa","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, European Institute of Oncology, IRCCS , Milan ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Derio","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, European Institute of Oncology, IRCCS , Milan ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariateresa","family":"Lapresa","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, European Institute of Oncology, IRCCS , Milan ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Gigli","sequence":"additional","affiliation":[{"name":"Division of Haematology Oncology, European Institute of Oncology, IRCCS , Milan ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"Parma","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, European Institute of Oncology, IRCCS , Milan ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuela","family":"Omodeo Sal\u00e8","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, European Institute of Oncology, IRCCS , Milan ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Derenzini","sequence":"additional","affiliation":[{"name":"Division of Haematology Oncology, European Institute of Oncology, IRCCS , Milan ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1781-2518","authenticated-orcid":false,"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[{"name":"Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS , Milan ,","place":["Italy"]},{"name":"University of Milan Department of Oncology and Hemato-Oncology, , Milan ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2225-715X","authenticated-orcid":false,"given":"Nicoletta","family":"Colombo","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, European Institute of Oncology, IRCCS , Milan ,","place":["Italy"]},{"name":"University of Milano-Bicocca Department of Medicine and Surgery, , Monza ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,11,28]]},"reference":[{"key":"2025073103164623600_CIT0001","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S0140-6736(18)32552-2","article-title":"Epithelial ovarian cancer","volume":"393","author":"Lheureux","year":"2019","journal-title":"Lancet (London, England)"},{"key":"2025073103164623600_CIT0002","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1038\/ejhg.2016.93","article-title":"The biological effects and clinical implications of BRCA mutations: where do we go from here","volume":"24","author":"Stoppa-Lyonnet","year":"2016","journal-title":"Eur J Human Genet"},{"key":"2025073103164623600_CIT0003","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/ng953","article-title":"BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair","volume":"32","author":"Hartman","year":"2002","journal-title":"Nat Genet"},{"key":"2025073103164623600_CIT0004","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1200\/EDBK_238977","article-title":"The role of BRCA testing in hereditary pancreatic and prostate cancer families","volume":"39","author":"Pilarski","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2025073103164623600_CIT0005","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/s0092-8674(02)00615-3","article-title":"Cancer susceptibility and the functions of BRCA1 and BRCA2","volume":"108","author":"Venkitaraman","year":"2002","journal-title":"Cell"},{"key":"2025073103164623600_CIT0006","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1056\/nejme0903044","article-title":"Synthetic lethality \u2014 a new direction in cancer-drug development","volume":"361","author":"Iglehart","year":"2009","journal-title":"N Engl J Med"},{"key":"2025073103164623600_CIT0007","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1126\/science.297.5588.1837","article-title":"BRCA2 Function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure","volume":"297","author":"Yang","year":"2002","journal-title":"Science"},{"key":"2025073103164623600_CIT0008","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13058-016-0709-1","article-title":"Increased chromosomal radiosensitivity in asymptomatic carriers of a heterozygous BRCA1 mutation","volume":"18","author":"Baert","year":"2016","journal-title":"Breast Cancer Res"},{"key":"2025073103164623600_CIT0009","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ygyno.2019.04.009","article-title":"Is BRCA mutational status a predictor of platinum-based chemotherapy related hematologic toxicity in high-grade serous ovarian cancer patients","volume":"154","author":"Tomao","year":"2019","journal-title":"Gynecol Oncol"},{"key":"2025073103164623600_CIT0010","doi-asserted-by":"publisher","first-page":"6400","DOI":"10.1158\/1078-0432.CCR-17-0703","article-title":"Differential toxicity in patients with and without DNA repair mutations: phase I study of carboplatin and talazoparib in advanced solid tumors","volume":"23","author":"Dhawan","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2025073103164623600_CIT0011","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s10549-018-05127-2","article-title":"BRCA1\/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients","volume":"174","author":"Friedlaender","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"2025073103164623600_CIT0012","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1159\/000354834","article-title":"The influence of BRCA1\/BRCA2 mutations on toxicity related to chemotherapy and radiotherapy in early breast cancer patients","volume":"85","author":"Huszno","year":"2013","journal-title":"Oncology (Huntingt)"},{"key":"2025073103164623600_CIT0013","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/igc.0000000000001144","article-title":"BRCA mutation status is not associated with increased hematologic toxicity among patients undergoing platinum-based chemotherapy for ovarian cancer","volume":"28","author":"Kotsopoulos","year":"2018","journal-title":"Int J Gynecol Cancer"},{"key":"2025073103164623600_CIT0014","doi-asserted-by":"publisher","first-page":"7033","DOI":"10.1158\/1078-0432.ccr-06-1246","article-title":"Acute chemotherapy\u2013related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for Breast Cancer in the United Kingdom","volume":"12","author":"Shanley","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2025073103164623600_CIT0015","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s10549-016-3777-0","article-title":"Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancer","volume":"156","author":"Drooger","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"2025073103164623600_CIT0016","doi-asserted-by":"publisher","first-page":"381","DOI":"10.5114\/wo.2016.64597","article-title":"Treatment related toxicity in BRCA1-associated epithelial ovarian cancer \u2013 is DNA repairing impairment associated with more adverse events","volume":"5","author":"Badora-Rybicka","year":"2016","journal-title":"Wsp\u00f3\u0142czesna Onkologia"},{"key":"2025073103164623600_CIT0017","doi-asserted-by":"publisher","first-page":"5609","DOI":"10.1002\/cam4.2471","article-title":"Hematologic toxicity in BRCA1 and BRCA2 mutation carriers during chemotherapy: a retrospective matched cohort study","volume":"8","author":"West","year":"2019","journal-title":"Cancer Med"},{"key":"2025073103164623600_CIT0018","doi-asserted-by":"publisher","first-page":"e1471","DOI":"10.1634\/theoncologist.2019-0272","article-title":"Chemotherapy toxicity in BRCA mutation carriers undergoing first-line platinum-based chemotherapy","volume":"24","author":"Weitzner","year":"2019","journal-title":"Oncologist"},{"key":"2025073103164623600_CIT0019","doi-asserted-by":"publisher","first-page":"5328","DOI":"10.3390\/cancers13215328","article-title":"PARP inhibitors and haematological malignancies\u2014friend or foe","volume":"13","author":"Skelding","year":"2021","journal-title":"Cancers"},{"key":"2025073103164623600_CIT0020","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/nejmoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med"},{"key":"2025073103164623600_CIT0021","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/s1470-2045(21)00073-5","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Poveda","year":"2021","journal-title":"Lancet Oncol"},{"key":"2025073103164623600_CIT0022","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/nejmoa1903387","article-title":"Maintenance olaparib for germline BRCAmutated metastatic pancreatic cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N Engl J Med"},{"key":"2025073103164623600_CIT0023","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"key":"2025073103164623600_CIT0024","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/nejmoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"key":"2025073103164623600_CIT0025","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/nejmoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N Engl J Med"},{"key":"2025073103164623600_CIT0026","doi-asserted-by":"publisher","first-page":"5328","DOI":"10.3390\/cancers13215328","article-title":"PARP inhibitors and haematological malignancies\u2014friend or Foe","volume":"13","author":"Skelding","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025073103164623600_CIT0027","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1111\/jcpt.13349","article-title":"Haematologic toxicities with PARP inhibitors in cancer patients: an up-to-date meta-analysis of 29 randomized controlled trials","volume":"46","author":"Wang","year":"2021","journal-title":"J Clin Pharm Ther"},{"key":"2025073103164623600_CIT0028","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1016\/s0090-8258(21)00700-9","article-title":"ORZORA: maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status","volume":"162","author":"Pignata","year":"2021","journal-title":"Gynecol Oncol"},{"key":"2025073103164623600_CIT0029","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/S1470-2045(11)70214-5","article-title":"Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study","volume":"12","author":"Gelmon","year":"2011","journal-title":"Lancet Oncol"},{"key":"2025073103164623600_CIT0030","doi-asserted-by":"publisher","first-page":"118434","DOI":"10.1016\/j.lfs.2020.118434","article-title":"Application and reflection of genomic scar assays in evaluating the efficacy of platinum salts and PARP inhibitors in cancer therapy","volume":"261","author":"Gou","year":"2020","journal-title":"Life Sci"},{"key":"2025073103164623600_CIT0031","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.annonc.2022.06.011","article-title":"Efficacy of subsequent chemotherapy for patients with BRCA1\/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2\/ENGOT Ov-21 trial","volume":"33","author":"Frenel","year":"2022","journal-title":"Ann Oncol"},{"key":"2025073103164623600_CIT0032","doi-asserted-by":"publisher","first-page":"5550","DOI":"10.1200\/jco.2023.41.16_suppl.5550","article-title":"Efficacy of subsequent therapies in patients (pts) with advanced ovarian cancer (AOC) in the phase III PAOLA-1\/ENGOT-ov25 trial according to whether disease progression occurred during or after the end of olaparib (ola) maintenance","volume":"41","author":"Harter","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025073103164623600_CIT0033","doi-asserted-by":"publisher","first-page":"112944","DOI":"10.1016\/j.ejca.2023.112944","article-title":"Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments","volume":"190","author":"Valenza","year":"2023","journal-title":"Eur J Cancer"},{"key":"2025073103164623600_CIT0034","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41586-024-07217-2","article-title":"Transcription\u2013replication conflicts underlie sensitivity to PARP inhibitors","volume":"628","author":"Petropoulos","year":"2024","journal-title":"Nature"},{"key":"2025073103164623600_CIT0035","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.annonc.2020.10.471","article-title":"Neoadjuvant paclitaxel\/olaparib in comparison to paclitaxel\/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)","volume":"32","author":"Fasching","year":"2021","journal-title":"Ann Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/7\/oyae330\/60897651\/oyae330.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/7\/oyae330\/60897651\/oyae330.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T07:16:53Z","timestamp":1753946213000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyae330\/7912471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,28]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7,4]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyae330","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"type":"print","value":"1083-7159"},{"type":"electronic","value":"1549-490X"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2024,11,28]]},"article-number":"oyae330"}}